Clinical trials: Nutritional Risk
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Coronary Artery Disease
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Patients with a known history of diabetes mellitus and no prior documented evidence of cardiovascular disease will be evaluated for inclusion in the study.
- Trial name
- faCTor-64 (NCT00488033)
- Testing
- CT Angiography
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- Intermountain Health Care, Inc.
Diabetes, Diabetes Mellitus, Type 2
Mindfulness IN-home for Diabetes and Sleep Health
The study investigates the effects of a mindfulness intervention on sleep and subsequent cardio-metabolic risk in an adult Atlanta population aged 18 and older.
- Trial name
- MINDS (NCT04160078)
- Testing
- Mindfulness-based stress reduction (MBSR) Intervention
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University